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Breast cancer is the most common malignancy in women and the leading cause of cancer deaths in women worldwide.
Breast cancers are heterogenous and exist in many different subtypes (luminal A, luminal B, triple negative, and human
epidermal growth factor receptor 2 (HER2) overexpressing), and each subtype displays distinct characteristics, responses
to treatment, and patient outcomes. In addition to varying immunohistochemical properties, each subtype contains a
distinct gene mutation profile which has yet to be fully defined. Patient treatment is currently guided by hormone
receptor status and HER2 expression, but accumulating evidence suggests that genetic mutations also influence drug
responses and patient survival. Thus, identifying the unique gene mutation pattern in each breast cancer subtype will
further improve personalized treatment and outcomes for breast cancer patients. In this study, we used the Ion Personal
Genome Machine (PGM) and Ion Torrent AmpliSeq Cancer Panel to sequence 737 mutational hotspot regions from 45
cancer-related genes to identify genetic mutations in 80 breast cancer samples of various subtypes from Chinese patients.
Analysis revealed frequent missense and combination mutations in PIK3CA and TP53, infrequent mutations in PTEN, and
uncommon combination mutations in luminal-type cancers in other genes including BRAF, GNAS, IDH1, and KRAS. This
study demonstrates the feasibility of using Ion Torrent sequencing technology to reliably detect gene mutations
in a clinical setting in order to guide personalized drug treatments or combination therapies to ultimately target
individual, breast cancer-specific mutations.
Keywords: Breast cancer, Genetic mutations, Ion torrent sequencing, Targeted therapy, Personalized medicineIntroduction
Breast cancer is the second most common malignancy
worldwide and the most frequent in women. Roughly
1.67 million new cases and 522,000 deaths were reported
globally in 2012, making breast cancer the fifth leading
cause of cancer death. Breast cancer incidence differs
with population and geographic location, where China
alone accounted for more than 187,000 cases and nearly
48,000 deaths in 2012, whereas over 230,000 cases and
more than 43,000 deaths were reported in the US [1].* Correspondence: zhoutao1967@163.com; siyichen@usc.edu
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unless otherwise stated.Patient screening is superior in the US than in China [2],
which may account for a higher incidence despite a much
smaller population. While risk factors for developing
breast cancer include ethnicity, older age, and environ-
mental factors, lifestyle and diet also play a significant role,
where westernization in Asia is thought to have contrib-
uted to the rise in spontaneous breast cancer incidence in
Chinese populations over the last 20 years [3-5].
Breast cancers are highly heterogenous and may display
different characteristics of hormone receptors (HR)
(estrogen receptor (ER) and progesterone receptor
(PR)) and human epidermal growth factor receptor 2
(HER2) status, and together this information helps to
distinguish different types of breast cancers: luminal A
(HR+/HER2−, tumor grade 1 or 2), luminal B/HER2−
(HR+/HER2−, tumor grade 3 or 4), luminal B/HER2+s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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overexpressing (HR−/HER2+) [6]. Together luminal A
and B subtypes account for 65%–70% of all breast can-
cers, whereas 10%–15% are triple negative and 10%–
20% are HER2 overexpressing [7].
These distinct types of breast cancers all have different
characteristics, behaviors, and prognoses and also re-
spond differently to drug treatments. Nearly three quar-
ters of all breast cancers are ER+ and are therefore in
some way dependent on estrogen for growth, providing
a useful target for treating these cancers via ER modula-
tors or downregulators or aromatase inhibitors [8]. But
only 20%–40% of patients with advanced ER+ breast
cancer have a response to endocrine therapy, which only
averages 8 to 14 months [9]. Luminal A types tend to
have the best outcome with a 95% 5-year survival rate,
whereas luminal B tumors, which tend to have lower HR
expression and subsequently less sensitivity to endocrine
therapy but increased sensitive to chemotherapy, tend to
have a worse outcome [10-12]. Typically found in youn-
ger patients, triple-negative breast cancers (TNBCs) are
known to be particularly aggressive and are associated
with germline BRCA mutations. TNBCs also have higher
relapse rates and decreased overall patient survival than
other breast cancer types [13]. HER2-overexpressing
breast cancers also have poor prognoses and high metas-
tases rates, and as they lack HR expression, they do not
respond to endocrine therapies and are resistant to
current chemotherapies [14]. These distinct breast cancer
types can be further divided into a multitude of subtypes,
and all of these types and subtypes exhibit distinct gene
mutation patterns that have yet to be fully defined [10].
Currently, patient prognoses and treatment regimens for
breast cancer are guided by the aforementioned character-
istics of the tumor, but accumulating evidence suggests
that this information is not enough; risk assessments,
treatments, and patient outcomes are also influenced by
both germline and somatic gene mutations. Known gen-
etic factors like inherited BRCA mutations confer a life-
time risk of developing breast cancer of 60% to 85%;
however, these mutations account for only 2%–3% of all
breast cancer cases [15]. Spontaneous mutations in
PIK3CA are a much more common event in breast can-
cers, with more than a quarter of breast cancer patients
harboring a mutation in this gene [16,17]. While PIK3CA
mutations have been shown to be associated with im-
proved patient prognoses, these genetic aberrations have
also been shown to impart resistance to trastuzumab, a
common treatment option for HER2-overexpressing
breast cancers [18]. Identifying gene mutations in patients
with TNBC is especially important because these cancers
currently do not have direct targets for treatments. There-
fore, it is important to establish both the immunohisto-
chemical properties and genetic profile of each breastcancer tumor to optimize treatment regimens and avoid
unnecessary drug toxicities and ultimately to improve pa-
tient outcomes.
There are a number of different next-generation se-
quencing (NGS) platforms available, including Illumina,
454, and SOLiD, but these are typically expensive both
in instrument and assay cost, and therefore, these tools
are unrealistic for widespread clinical diagnostic use. But
new technology like the Ion Torrent sequencing plat-
form has been shown to be more cost and time effective
with reliable results [19], which may help make cancer
DNA sequencing and personalized treatments a reality
for each cancer patient in the near future. In the present
study, we have used Ion Torrent sequencing technology
with the Ion Personal Genome Machine (PGM) and Ion
Torrent AmpliSeq Cancer Panel as a rapid and afford-
able method to detect gene mutations in 80 clinical
breast cancer samples of different types from Chinese
patients.Materials and methods
Ethics statement
The study has been approved by the Human Research
Ethics Committee of the First Affiliated Hospital of Dalian
Medical University, China. The institutional ethics com-
mittee waived the need for consent for formalin-fixed,
paraffin-embedded (FFPE) tumor samples obtained from
the tumor tissue bank at the hospital’s Department of
Pathology. All samples and medical data used in this study
have been irreversibly anonymized.
Patient information
Tumor samples used in the study were collected from
the First Affiliated Hospital of Dalian Medical University,
China. A total of 80 FFPE tumor samples from Chinese
breast cancer patients were analyzed (Table 1). Patients
were an average of 55 years old, with a range of 30–75
years. American Joint Committee on Cancer (AJCC)/
tumor, node, and metastasis (TNM) cancer staging was
assessed, and tumor samples were also analyzed for im-
munohistochemical status of HR and HER2 (Table 1).
Based on these, patients were categorized into five breast
cancer subtypes: luminal A (HR+/HER2−, AJCC stage 1
or 2; 26.3%), luminal B/HER2− (HR+/HER2−, AJCC
stage 3 or 4; 21.3%), luminal B/HER2+ (HR+/HER2+;
30.0%), triple negative (HR−/HER2−; 7.5%), and HER2
overexpressing (HR−/HER2+; 8.8%), and five samples
(6.3%) were unclassifiable due to unknown HER2 status
(Table 2).
DNA preparation
FFPE tissue samples were first deparaffinized in xylene,
3–5-μm-thick sections were extracted, and DNA was
Table 1 Clinical features of 80 breast cancer patients
Characteristic n (%)
Age (years) Median: 56
Range: 30–75
HR status HR+ 65 (81.3%)
HR− 15 (18.8%)
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per the manufacturer’s instructions.Ion Torrent PGM library preparation and DNA sequencing
An Ion Torrent adapter-ligated library was constructed
with the Ion AmpliSeq Library Kit 2.0 (Life Technolo-
gies, Part #4475345 Rev. A) following the manufacturer’s
protocol. Briefly, 50 ng of pooled amplicons were end-Table 2 Average patient age, average disease-free survival (D























54.5 38.3 32 (40.0%) 48 (60.0%) 5
Luminal A 21
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52.9 37.3 11 (45.8%) 13 (54.2%) 5
Triple negative 6
(7.5%)





56.6 34.6 2 (28.6%) 5 (71.4%) 5
Unknown 5
(6.3%)
59.0 43.0 0 (0.0%) 5 (100%) -repaired, Ion Torrent adapters P1 and A were ligated,
and the adapter-ligated products were then purified with
AMPure beads (Beckman Coulter, Brea, CA, USA), nick-
translated, and PCR-amplified for 5 cycles. The resulting
library was purified with AMPure beads (Beckman
Coulter), and the library concentration and size was de-
termined with the Agilent 2100 Bioanalyzer and Agilent
Bioanalyzer DNA High-Sensitivity LabChip (Agilent
Technologies).
Sample emulsion PCR, emulsion breaking, and enrich-
ment were performed with the Ion PGM 200 Xpress
Template Kit (Life Technologies, Part #4474280 Rev. B),
according to the manufacturer’s instructions. Briefly, an
input concentration of one DNA template copy/Ion
Sphere Particles (ISPs) was added to emulsion PCR mas-
ter mix, and the emulsion was generated with an
IKADT-20 mixer (Life Technologies). Next, ISPs were
recovered, and template-positive ISPs were enriched
with Dynabeads MyOne Streptavidin C1 beads (Life
Technologies). The Qubit 2.0 fluorometer (Life Tech-
nologies) was used to confirm ISP enrichment. Three-
hundred sixteen chips were used to sequence barcoded
samples on the Ion Torrent PGM for 65 cycles, and an
Ion PGM 200 Sequencing Kit (Life Technologies, Part #
4474004 Rev. B) was used for sequencing reactions, as
per the recommended protocol.
This Personalized Cancer Mutation Panel targets 737
mutational hotspot regions in the following 45 genes:
ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A,
CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7,
FGFR1, FGFR2, FGFR3, FLT3, GNAS, HNF1A, HRAS,
IDH1, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL,





















4.9 54.2 0.757 38.8 38.0 0.741
3.8 53.7 0.979 40.6 37.8 0.407
7.3 54.9 0.626 40.5 38.7 0.799
3.6 52.3 0.772 37.5 37.1 0.936
8.8 44.0 0.165 39.8 33.0 0.508
2.5 58.2 0.633 31.5 35.8 0.595
59.0 - - 43.0 -
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STK11, TP53, and VHL.Variant calling
Initial data from the PGM runs were processed with
the Ion Torrent platform-specific pipeline software
Torrent Suite to generate sequence reads, then trim
adapter sequences, filter, and remove poor signal-
profile reads. Torrent Suite software v3.4 with a plug-in
“variant caller v3.4” program was used to generate ini-
tial variant calling from the Ion AmpliSeq sequencing
data. In order to eliminate erroneous base calling and
generate final variant calling, several filtering steps
were used: defining average total coverage depth, vari-
ant coverage, variant frequency of each sample, and PFigure 1 Sequence read distribution across 189 amplicons generated
sample. (A) Average number of reads observed for each amplicon. (B) Nuvalue <0.01; visually inspecting and removing DNA
strand-specific errors; defining variants within hotspots;
and eliminating variants in amplicon AMPL339432
(PIK3CA, exon13, chr3:178938822–178938906) which
is not uniquely matched in the human genome.Sequence coverage
From the 80 samples, the mean read length was 76 bp
and the average reads were approximately 24 Mb of se-
quence per sample. With normalization to 300,000 reads
per specimen, there was an average of 1,639 reads per
amplicon (range: 22 to 6,020) (Figure 1A); 180/189
(95.2%) amplicons averaged at least 100 reads; and 170/
189 (89.9%) amplicons averaged at least 300 reads
(Figure 1B).from 80 breast cancer samples, normalized to 300,000 reads per
mber of targets with a given read depth, sorted in bins of 100 reads.
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Detected mutations were compared to variants in the 1000
Genomes Project [20] and 6,500 exomes of the National
Heart, Lung, and Blood Institute Exome Sequencing Pro-
ject [21] to distinguish between somatic and germline
mutations.
Bioinformatical and experimental validation
We used the COSMIC [22] (version 64), MyCancer-
Genome database (http://www.mycancergenome.org/),
and some publications to assess recurrent mutations in
breast cancer (Additional file 1: Table S1). Additionally,
detected missense mutations were confirmed by Sanger
sequencing (data not shown). All mutations identified
with Sanger sequencing were consistent with those
identified with the Ion Torrent PGM.
Statistical analysis
The Fisher’s exact test was used to define significant
values in the detected mutated genes, and the total vari-
ants and odds ratios (OR) between samples with muta-
tions and without mutations were determined using 2 ×
2 contingency tables and the GraphPad QuickCalcs on-
line calculator for Scientists (http://www.graphpad.com/
quickcalcs/index.cfm). All P values are two-sided, and
statistical significance was defined as P < 0.05.
Results and discussion
From the 45 genes screened in our study, 39 mutations
were detected in 32 of 80 samples (40.0%) (Figure 2).
Except for the five unclassified samples with noFigure 2 Summary of mutated genes detected in 80 breast cancer sa
BRAF, PTEN, GNAS, and IDH1. Samples are classified by four methods: 1) Imm
IDC3, other); 3) AJCC/TNM-staging (2a, 2b, 3a, 3b, 3c, 4); and 4) recurrencemutations, mutations were detected at different fre-
quencies across all breast cancer subtypes (Table 2).
Triple negative samples contained the highest mutation
frequency (66.7%), whereas HER2-overexpressing sam-
ples contained the lowest mutation frequency (28.6%),
and luminal A, luminal B/HER2−, and luminal B/HER2+
had similar mutation frequencies (42.9%, 35.3%, and
45.8%, respectively). Twenty-six samples (32.5%) con-
tained one mutation, five samples (6.3%) contained two
mutations, and one sample (1.3%) contained three muta-
tions, and interestingly, combination mutations were only
found in the luminal subtypes (Table 3). PIK3CA muta-
tions and TP53 mutations were the most prevalent (32.5%
and 10.0%, respectively), and mutations were also identi-
fied in BRAF, GNAS, IDH1, KRAS, and PTEN all at a fre-
quency of 1.3% (Figure 3). Among each subtype, there was
no statistically significant difference in age or disease-free
survival (DFS) between patients with mutations and
patients without mutations (Table 2).
PIK3CA mutations
Twenty-six samples (32.5%) harbored PIK3CA muta-
tions, which accounted for 66.7% of all detected muta-
tions in our study. Five different PIK3CA mutations
were identified: p.N345K in the C2 domain encoded by
exon 4, p.E542K and p.E545K in the helical domain
encoded by exon 9, and p.H1047R and p.H1047L in the
kinase domain encoded by exon 20. Mutations p.E542K,
p.E545K, and p.H1047R have been found in previous stud-
ies to be the most prevalent in human breast cancers and
are associated with an increase in kinase activity in themples. Thirty-two samples harbor mutations in PIK3CA, TP53, KRAS,
unohistochemistry of ER, PR, and HER2; 2) pathologic type (IDC2,
or no recurrence.
Table 3 Detected point mutations per breast cancer subtype
Breast cancer type Gene(s) Mutation(s) Age (years) DFS (months) Recurrence AJCC ER PR HER2
Luminal A PIK3CA p.N345K 62 36 N 2a + + −
PIK3CA p.E545K 46 36 N 2a + + −
PIK3CA p.E545K 61 47 N 2a + + −
PIK3CA p.H1047L 55 36 N 2b + + −
PIK3CA p.H1047R 51 48 N 2a + + −
PIK3CA p.H1047R 46 42 N 2a + + −
PIK3CA p.H1047R 56 36 N 2a + − −
PIK3CA/TP53 p.H1047R/p.R248W 57 41 N 2a + + −
PIK3CA/TP53 p.H1047R/p.R175H 50 36 Y 2b + + −
Luminal B/HER2− PTEN p.T321fs*23 55 28 Y 3c + + −
PIK3CA/TP53 p.E545K/ p.H193R 52 53 N 3c + + −
PIK3CA/BRAF p.H1047R/ p.V600M 59 36 Y 3b + + −
PIK3CA p.H1047R 52 36 N 3a + + −
PIK3CA p.H1047R 58 36 N 3a + + −
PIK3CA p.H1047R 68 54 N 3a + + −
Luminal B/HER2+ GNAS/IDH1/KRAS p.R201C/ p.R132C/ p.G12D 57 36 N 2a + + +
PIK3CA p.E542K 50 47 N 3a + + +
PIK3CA p.E545K 66 42 N 2b + + +
PIK3CA p.H1047L 72 40 N 3a + + ++
PIK3CA p.H1047R 44 36 N 2a + + +
PIK3CA p.H1047R 45 55 N 2a + + +
PIK3CA p.H1047R 32 36 N 2a + − +
PIK3CA p.H1047R 65 25 Y 3a + + ++
PIK3CA p.H1047R 63 12 Y 3c + + ++
PIK3CA/TP53 p.H1047R/ p.P278L 49 41 N 3a + + ++
TP53 p.Y220C 47 43 N 2a + + +
Triple negative PIK3CA p.E545K 60 43 N 2b − − −
PIK3CA p.E542K 61 26 Y 4 − − −
TP53 p.Y163C 57 40 N 2a − − −
TP53 p.R196* 57 50 N 2b − − −
HER2 overexpressing PIK3CA p.H1047R 65 20 Y 3c − − +
TP53 p.R213* 40 43 N 2b − − ++
DFS disease-free survival, del deletion, fs frameshift.
*Nonsense mutation resulting in a stop codon.
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for 88.5% of all PIK3CA mutations in our study. The
remaining mutations, p.N345K and p.H1047L, are much
less common and are found in less than 2% and 3.5% of
breast cancers, respectively [22,25,26].
PIK3CA mutations are an early event in breast cancer
development. Accordingly, we found mutations in this
gene at all stages and all breast cancer subtypes in our
study. While previous research has found PIK3CA muta-
tions to be associated with older patient age [25], we did
not find significant differences between age and PIK3CA
mutations among all patients or breast cancer subtypes.Consistent with a study by Kalinsky et al. [25], PIK3CA
mutations were found in more HER2− tumors than
HER2+ tumors (61.5% vs. 38.5%, respectively), although
not significantly (OR: 1.20; P = 0.81). Also, patients with
HR+ tumors had a higher likelihood of having a PIK3CA
mutation than those with HR− tumors, but again, this
was not statistically significant (OR: 2.19; P = 0.36).
Others have found lower PIK3CA mutation frequencies
in luminal B than luminal A breast cancers [10], but we
found the opposite in our study with 53.8% of PIK3CA-
mutated samples as luminal B types vs. 34.6% luminal A
type. Drugs like everolimus, a rapamycin derivative that
Figure 3 Signaling pathways in breast cancer with gene
mutations. Genetic alterations in breast cancer primarily occur in
genes of the MAPK, p53, and PI3K/AKT signaling pathways.
Alterations in oncogenes are indicated in pink, and those in cancer
suppressor genes are shown in green. Percentages (%) are the
frequency of mutations per gene in our study out of 80 samples.
Tyrosine kinase receptors (TKRs) include HER2, EGFR, and IGF-1R in
breast cancer.
Liu et al. Human Genomics  (2015) 9:2 Page 7 of 10inhibits PI3K/ATK/mTOR signaling, have been approved
to treat advanced HR+/HER2− breast cancer patients after
other treatments have failed and have been shown to
increase progression-free survival [27-29].
While the study of Kalinsky et al. found overall patient
survival to be significantly improved in patients with
PIK3CA mutations [25], we found that patients with
PIK3CA mutations collectively had a roughly equal DFS
time to patients with WT PIK3CA (38.6 vs. 38.2 months,
respectively); however, patients with triple negative and
HER2-overexpressing tumors and PIK3CA mutations had
a shorter average DFS (34.5 and 20 months, respectively)
than those with WT PIK3CA (39 and 37 moths, re-
spectively), possibly suggesting that the other charac-
teristics of the tumor may have greater prognostic value
than PIK3CA mutations. Consistent with a clinical study
on the impact of specific PIK3CA mutations on breast
cancer patient prognosis [30], we found that patients with
PIK3CA mutations in exon 20 had a slightly shorter DFS
than those with PIK3CA mutations in exons 4 and 9 (37.4
vs. 41.3 months, respectively; P = 0.37). Because activation
of the PI3K/ATK/mTOR pathway has been shown to con-
fer resistance to trastuzumab treatment in HER2+ breast
tumors [31,32], and because the specific mutation may
offer prognostic value, it is important to identify PIK3CAmutations in all breast cancer patients regardless of
subtype.
TP53 mutations
Eight samples (10.0%) were found to harbor TP53 muta-
tions, and these mutations were identified in each sub-
type: 2 (9.5%) in luminal A, 1 (5.9%) in luminal B/
HER2−, 2 (8.3%) in luminal B/HER2+, 2 (33.3%) in
triple negative, and 1 (14.3%) in HER2-overexpressing
tumors. There was no statistically significant difference
between age and TP53 mutations among all patients or
breast cancer subtypes, nor was there a difference in
DFS and TP53 mutations and subtype. Among 80 sam-
ples, we found TP53 mutations were more likely to
occur in HR− tumors (OR: 3.0; P = 0.17) and tumors of
a lower grade (75.0% at stage 2 vs. 25.0% at 3 or 4; OR:
2.54; P = 0.46). Five of the eight (62.5%) TP53-mutated
tumors were HER2−, although study wide, there was
no correlation between TP53 mutations and HER2 sta-
tus (OR: 1.25; P = 1.0). Others have reported that TP53
is associated with worse overall patient survival
[33-35], but we found this to be the opposite in our
study; across all types, patients with TP53 mutations
had an average DFS of 44.3 vs. 37.7 months for those
with WT TP53 (P = 0.09).
The eight different TP53 mutations detected in our
study were found at known hotspot locations, all within
the DNA binding domains: two in exon 5 (p.Y136C and
p.R175H); four in exon 6 (p.H193R, p.R196*, p.R213*,
and p.Y220C); one in exon 7 (p.R248W); and one in
exon 8 (p.P278L). Mutations in exons 5 and 7 have pre-
viously been shown to correlate with poorer overall sur-
vival and disease-free progression in breast cancer
patients [36,37]. Specifically, mutations in these exons
which affect the L2 and L3 loop domains of the protein
(codons 163–195 and 236–251, respectively) have been
found to confer resistance to certain cytotoxic drugs,
including 5-fluorouracil and mitomycin [38,39]. How-
ever, in our study, there were only four patients with
TP53 mutations in these exons and specific codons,
and these patients had an equal DFS to patients with
other TP53 mutations (44.3 months), and a longer,
albeit not significant, DFS than the study average of
38.3 months (P = 0.26).
Combination and less frequent mutations
One advanced luminal B/HER2− sample contained a de-
letion in codon 321, exon 8 of PTEN, resulting in a
frameshift mutation (p.T321fs*23). This mutation has
been found in other cancers of the endometrium and
large intestine but has not yet been identified in breast
cancers [22]. As an antagonist of PI3K signaling, im-
proper PTEN function leads to uncontrolled activation
of its downstream signals [16], and reduced PTEN
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and is associated with advanced disease [40,41]. Ac-
cordingly, the PTEN-mutated sample in our study was
stage 3C, and the patient’s DFS was 10 months shorter
that the study average. Others have reported that
PTEN mutations occur more often in HR− tumors
[41,42], which was not the case for the PTEN-mutated
sample in our study.
Six of the samples (7.5%) contained mutations in a
combination of genes, and all co-mutations were found
in the luminal subtypes (100% HR+, 66.7% HER2−)
(Table 3). Five of the six combination mutations co-
occurred with PIK3CA, and four of these were a com-
bination of PIK3CA and TP53. Research suggests that
the presence of PIK3CA and TP53 co-mutations in-
crease breast cancer sensitivity to some PI3K/AKT/
mTOR inhibitors when compared to those with PIK3CA
mutations alone [43,44]; regardless, promising drugs like
BEZ235, a PI3K/mTOR kinase inhibitor, may only be
effective in a specific subset of triple-negative breast
cancers [45].
One luminal B/HER2− sample harbored a combination
mutation in PIK3CA (p.H1047R) and BRAF (p.V600M).
This combination is commonly found in melanoma but
rarely in breast cancer [46]. The vast majority of BRAF
mutations identified in all cancer types are activating
mutations that occur at codon 600, most commonly p.
V600E (84.6%), whereas p.V600M accounts for only
0.3% of BRAF mutations at this codon [47]. While this
mutation is not common in breast cancers, several
drugs have been developed to target BRAF mutations
in other cancer types and are showing promising results in
breast cancer models [48,49]. By combining treatments to
target both PIK3CA and BRAF mutations, patients with
combination mutations such as these may find benefit
greater than a single treatment. Everolimus, however,
would not be effective because research has shown this
drug to be ineffective in the presence of a KRAS or BRAF
mutation [27].
One stage 2A luminal B/HER2+ sample contained a
unique combination of mutations in three different genes,
GNAS (p.R201C), IDH1 (p.R132C), and KRAS (p.G12D), a
combination that, to our knowledge, has yet to be identi-
fied in breast cancer. GNAS mutations, which are com-
monly found in pituitary and pancreatic cancers, and IDH1
mutations, common in gliomas, are uncommon events in
breast cancers, both found in less than 1% [22,50]. KRAS
mutations are only slightly more common, found in 2%–
5% of breast cancers [22,51]. KRAS is involved in the EGFR
signaling pathway, and anti-EGFR drugs like lapatinib used
to treat advanced HER2+ breast cancers require WT KRAS
to be effective [52,53]. For a patient with these tumor char-
acteristics, knowledge of mutated KRAS status would
prevent unnecessary drug toxicity.Conclusion
Characterization of breast cancer tumors is critical in
determining appropriate treatment options and predict-
ing patient prognosis. The hormone receptor status and
HER2 expression act as markers to direct drug treat-
ments or to predict behavior of the disease. In addition
to immunohistochemical properties, it is becoming in-
creasingly evident that gene mutations play a role in
breast cancer progression and response to treatment,
making it critical to determine the genetic profile of each
breast cancer tumor to personalize treatments and
optimize patient outcomes. In our study, we used Ion
Torrent sequencing technology to identify mutations in
80 clinical breast cancer tumors of various subtypes.
Our study revealed not only uncommon and novel com-
bination mutations but also mutations commonly found
in breast cancers at frequencies similar to those previ-
ously reported, indicating the reliability of the Ion Tor-
rent sequencing method to genotype cancer samples in
a clinical setting. Ion Torrent sequencing technology has
also been shown to be more cost and time effective than
other traditional sequencing methods [19,54], and as
such, it may be a feasible way to advance personalized
patient treatments by providing clinicians a tool to
characterize breast cancers beyond immunohistochemi-
cal markers and ultimately improve outcomes for breast
cancer patients.
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